Clinical Trials Logo

Primary Immunodeficiency Disease clinical trials

View clinical trials related to Primary Immunodeficiency Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06150833 Not yet recruiting - Clinical trials for Primary Immunodeficiency Disease

Efficacy and Safety and Pharmacokinetics of Boya IVIG

Boya
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the safety, efficacy and pharmacokinetic properties of Boya's IVIG preparation in participants with PID aged less than 60 years and more than 6 years.

NCT ID: NCT06089122 Not yet recruiting - Clinical trials for Primary Immunodeficiency Disease

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Imunoforte
Start date: April 2024
Phase: Phase 3
Study type: Interventional

To evaluate the safety, efficacy, and pharmacokinetic properties of Shu Yang intravenous immune globulin in patients with primary immune deficiency aged less than 60 years. The main benefit of IVIG is to help the body fight against a large variety of infections generally associated with morbidity and mortality in patients with primary immunodeficiency diseases, particularly in CVID and XLA. In addition, a decrease in the number of infections, a reduction in medications and hospitalizations, and a better quality of life are expected. Throughout treatment, approximately one-fourth of persons may experience a side effect. These are usually mild or bothersome but not dangerous. Very rarely, more serious side effects like allergic reactions or low blood counts (anemia) can occur. One of the most common side effects is headache. Other side effects include chills, fever, flushing, flu-like muscle pains or joint pains, feeling tired, nausea, vomiting, and rash. For the most part, these reactions typically happen with the first dose of IVIG or because change to a different brand of IVIG. All IVIG products have similar warnings and contraindications, such as the potential for renal failure, thrombotic events, aseptic meningitis, hemolysis, and anaphylactic reactions.

NCT ID: NCT03252548 Not yet recruiting - Clinical trials for Primary Immunodeficiency Disease

Pediatric Primary Immunodeficiency Disease (PID) in China

Start date: January 2018
Phase: N/A
Study type: Observational

This study is a prospective cohort study of children diagnosed with primary immunodeficiency disease (PID). The aim is to investigate the clinical characteristics and prognosis of PID in Chinese children.